Destiny Pharma announces Brazilian Patent granted for XF-73 nasal gel

Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, today announces that Brazil’s Industrial Property Office has issued a notice of allowance that will now lead to the final approval in March of the Company’s patent application (Brazilian Patent Application no. PI 0512563-4) in relation to XF-73.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...